Edited by Peter CresswellSeveral antibody-targeting cancer immunotherapies have been developed based on T cell activation at the target cells.
One of the most potent activators of T cells are bacterial superantigens, which bind to major histocompatibility complex class II on antigen-presenting cells and activate T cells through T cell receptor. Strong T cell activation is also one of the main weaknesses of this strategy as it may lead to systemic T cell activation. To overcome the limitation of conventional antibody-superantigen fusion proteins, we have split a superantigen into two fragments, individually inactive, until both fragments came into close proximity and reassembled into a biologically active form capable of activating T cell response.A screening method based on fusion between SEA and coiledcoil heterodimers was developed that enabled detection of functional split SEA designs. The split SEA design that demonstrated efficacy in fusion with coiled-coil dimer forming polypeptides was fused to a single chain antibody specific for tumor antigen CD20. This design selectively activated T cells by split SEA-scFv fusion binding to target cells.Cancer therapy is experiencing great progress, especially based on application of biological drugs and cell immunotherapy. Nevertheless, cancer remains one of the leading causes of death in developed countries. In the last decade, immunotherapy became an important approach for fighting cancer, where the main goal is to activate the patient's own immune system to specifically recognize and kill tumor cells. Antibody-based therapeutics that target surface antigens expressed on tumor cells are successfully used for treatment of different types of cancer. Although unconjugated monoclonal antibodies are efficient, clinical studies showed that conjugating cytotoxic agents to monoclonal antibodies enhances their clinical utility (1). Antibody-drug conjugates are a class of highly potent biological drugs, composed of an antibody and an effector molecule. One of the immunotherapy approaches to potentiate the effects of monoclonal antibodies includes superantigens as effector molecules.